International Cancer Conference Journal最新文献_第10页

Delayed-onset immune-related colitis more than three years after nivolumab therapy for metastatic renal cell carcinoma: A case report. 纳沃单抗治疗转移性肾细胞癌后3年以上发生的延迟性免疫相关性结肠炎1例报告

IF 0.5

International Cancer Conference Journal Pub Date : 2025-04-12 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00762-1

Ken Shibata, Fumihiko Urabe, Gaku Kurokawa, Yuji Yata, Juria Nakano, Risako Ueha, Ruby Matsumoto, Makoto Okamoto, Hiroki Tanaka, Rie Ohtomo, Yusuke Koike, Takahiro Kimura

{"title":"Delayed-onset immune-related colitis more than three years after nivolumab therapy for metastatic renal cell carcinoma: A case report.","authors":"Ken Shibata, Fumihiko Urabe, Gaku Kurokawa, Yuji Yata, Juria Nakano, Risako Ueha, Ruby Matsumoto, Makoto Okamoto, Hiroki Tanaka, Rie Ohtomo, Yusuke Koike, Takahiro Kimura","doi":"10.1007/s13691-025-00762-1","DOIUrl":"10.1007/s13691-025-00762-1","url":null,"abstract":"Nivolumab, a PD-1 inhibitor, enhances anti-tumor immunity but can cause immune-related adverse events (irAEs). Although irAE-colitis usually occurs within 2-3 months of starting nivolumab, we report a rare case that developed 38 months after treatment initiation. A 75-year-old man with metastatic renal cell carcinoma received multiple lines of molecular targeted therapies before starting nivolumab. After progression of bone metastases, nivolumab was reinitiated and maintained a complete response of bilateral iliac bone metastases for three years. He subsequently developed Grade 3 diarrhea. Colonoscopy revealed diffuse inflammation from rectum to sigmoid colon, and pathological examination showed findings consistent with irAE-colitis. Prompt initiation of prednisolone 60 mg/day led to complete symptom resolution within two weeks. This case represents the first reported instance of irAE-colitis occurring after 38 months of nivolumab treatment. It is essential to conduct regular follow-up examinations and actively perform diagnostic tests when symptoms arise, ensuring vigilance for the potential occurrence of delayed-onset irAEs to facilitate appropriate management.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"259-263"},"PeriodicalIF":0.5,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of zolbetuximab-induced protein-losing gastroenteropathy in a patient with advanced gastric cancer. 唑苯妥昔单抗致晚期胃癌患者失蛋白性胃肠病1例。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-04-11 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00764-z

Kunihiro Tsuji, Kito Yosuke, Saori Miyajima, Sho Tsuyama

引用次数: 0

Two Japanese patients with metastatic castration-resistant prostate cancer with somatic biallelic BRCA2 loss and RB1 splice site variant or loss who responded to Poly-ADP-ribose polymerase inhibitor: A case report. 2例日本转移性去势抵抗性前列腺癌患者，伴有体细胞双等位基因BRCA2缺失和RB1剪接位点变异或缺失，对poly - adp核糖聚合酶抑制剂有反应：1例报告。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-04-10 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00761-2

Shiori Miyachi, Takeshi Sasaki, Momoko Kato, Katsunori Uchida, Shunsuke Owa, Taketomo Nishikawa, Shinichiro Higashi, Hiroto Yuasa, Kouhei Nishikawa, Yoshinaga Okugawa, Masatoshi Watanabe, Takahiro Inoue

{"title":"Two Japanese patients with metastatic castration-resistant prostate cancer with somatic biallelic BRCA2 loss and RB1 splice site variant or loss who responded to Poly-ADP-ribose polymerase inhibitor: A case report.","authors":"Shiori Miyachi, Takeshi Sasaki, Momoko Kato, Katsunori Uchida, Shunsuke Owa, Taketomo Nishikawa, Shinichiro Higashi, Hiroto Yuasa, Kouhei Nishikawa, Yoshinaga Okugawa, Masatoshi Watanabe, Takahiro Inoue","doi":"10.1007/s13691-025-00761-2","DOIUrl":"10.1007/s13691-025-00761-2","url":null,"abstract":"We treated two patients with metastatic castration-resistant prostate cancer (mCRPC) who achieved a response duration of more than 12 months with Poly-ADP-ribose polymerase inhibitor (PARPi). Case 1 was a patient in his 60s with lung metastases, and case 2 was in his 70s and presented liver metastases. Genetic tests (FoundationOne® CDx) were performed. Both patients had somatic biallelic BRCA2 loss, together with RB1 splice site variant (NM_000321.3:c.2489 + 1G > C) or RB1 loss. After PARPi administration, their metastatic sites had shrunk enough to keep partial response. These cases suggested that patients with mCRPC with biallelic BRCA2 loss and the RB1 splice site variant or loss may have remarkable response to PARPi.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"254-258"},"PeriodicalIF":0.5,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Continuous measurement of radioactivity for a patient with chronic kidney disease during radioactive iodine therapy and hemodialysis: a case report. 放射性碘治疗和血液透析期间慢性肾病患者放射性的连续测量：1例报告。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-04-09 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00756-z

Takuma Usuzaki, Hiroyasu Kodama, Mariko Miyazaki, Keiichi Jingu

{"title":"Continuous measurement of radioactivity for a patient with chronic kidney disease during radioactive iodine therapy and hemodialysis: a case report.","authors":"Takuma Usuzaki, Hiroyasu Kodama, Mariko Miyazaki, Keiichi Jingu","doi":"10.1007/s13691-025-00756-z","DOIUrl":"10.1007/s13691-025-00756-z","url":null,"abstract":"The half-life of radioactive iodine (RAI) is prolonged in patients with chronic kidney disease (CKD) because RAI is mainly excreted by the kidneys. There is little information on the RAI half-life in patients with dialysis-dependent CKD (CKDG5d). Estimating the RAI half-life in a patient's body provides important information for treatment planning. In this paper, we report a 68-year-old woman of CKDG5d who underwent postsurgical RAI therapy for papillary adenocarcinoma of the thyroid. We administered 15 mCi (0.56 GBq) RAI (131I) and continuously measured the dose equivalent rate. The results were summarized into hourly values of dose equivalent rate. Based on the measurements, we estimated the RAI half-life in the patient's body using a semi-log plot and linear regression analysis. In addition, we calculated the integrated doses for caregivers and the public using coefficients of 0.5 and 0.25, respectively. The half-life in the patient's body was 7.2 days (95% confidence interval, 4.8-14.4). The integrated doses for caregivers and the public were 0.23 mSv and 0.11 mSv, respectively. RAI therapy for a CKDG5d patient should be planned on the basis of the biological dynamics of 131I. Accumulation of more cases should lead to the establishment of a treatment strategy for patients undergoing RAI therapy and hemodialysis.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"220-228"},"PeriodicalIF":0.5,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Simultaneous malignant peripheral nerve sheath tumour and malignant melanoma of the anorectal region. 肛门直肠区同时发生恶性周围神经鞘瘤和恶性黑色素瘤。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-04-04 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00760-3

Nobuto Yamazaki, Yoshinori Kikuchi, Kimihiko Yoshida, Yasuyuki Miura, Takamaru Koda, Yasuo Nagashima, Takayuki Suzuki, Satoru Kagami, Tomoaki Kaneko, Hiroyuki Shiokawa, Nanako Inoue, Naoki Onda, Mitsunori Ushigome, Akiharu Kurihara, Yasuko Kurose, Naobumi Tochigi, Kimihiko Funahashi

{"title":"Simultaneous malignant peripheral nerve sheath tumour and malignant melanoma of the anorectal region.","authors":"Nobuto Yamazaki, Yoshinori Kikuchi, Kimihiko Yoshida, Yasuyuki Miura, Takamaru Koda, Yasuo Nagashima, Takayuki Suzuki, Satoru Kagami, Tomoaki Kaneko, Hiroyuki Shiokawa, Nanako Inoue, Naoki Onda, Mitsunori Ushigome, Akiharu Kurihara, Yasuko Kurose, Naobumi Tochigi, Kimihiko Funahashi","doi":"10.1007/s13691-025-00760-3","DOIUrl":"10.1007/s13691-025-00760-3","url":null,"abstract":"A 69-year-old male presented to our clinic with bloody faecal matter. Examination revealed a 60-mm type 1 tumour on the posterior rectal wall and a 15-mm type Is tumour on the anterior rectal wall. R0 resection was performed via laparoscopic perineal rectal resection (extraperitoneal colectomy). Immunohistochemical staining led to the diagnosis of anorectal malignant peripheral nerve sheath tumour on the posterior rectal wall and anorectal malignant melanoma on the anterior rectal wall. Peritoneal dissemination occurred 10 months after resection, with the appearance of liver tumours. The liver was biopsied and pathological examination revealed metastasis due to malignant peripheral nerve sheath tumours. Primary treatment with doxorubicin plus ifosfamide and secondary treatment with etoposide plus carboplatin were ineffective.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"246-253"},"PeriodicalIF":0.5,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of primary malignant melanoma of the ureter. 输尿管原发性恶性黑色素瘤1例。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-03-29 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00757-y

Masaharu Oki, Kojiro Ohba, Hiroyuki Honda, Shintaro Mori, Shota Kakita, Kyohei Araki, Kensuke Mitsunari, Tomohiro Matsuo, Yasushi Mochizuki, Ryoichi Imamura

引用次数: 0

Complete recovery from pseudocirrhosis caused by chemotherapy for diffuse liver metastases of breast cancer. 乳腺癌弥漫性肝转移化疗引起的假性肝硬化完全康复。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-03-28 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00759-w

Arimichi Kamata, Koji Hino, Kenichi Tazawa, Kimiko Kawai, Keiichi Arai, Atsushi Nakano

{"title":"Complete recovery from pseudocirrhosis caused by chemotherapy for diffuse liver metastases of breast cancer.","authors":"Arimichi Kamata, Koji Hino, Kenichi Tazawa, Kimiko Kawai, Keiichi Arai, Atsushi Nakano","doi":"10.1007/s13691-025-00759-w","DOIUrl":"10.1007/s13691-025-00759-w","url":null,"abstract":"Pseudocirrhosis refers to morphologic changes of the liver seen radiographically that mimic cirrhosis and arise in the setting of metastatic malignancy. Like true cirrhosis, pseudocirrhosis causes portal hypertension, which can lead to complications such as ascites and esophageal varices. We experienced a case of pseudocirrhosis that occurred during treatment for diffuse liver metastases from breast cancer. Pseudocirrhosis is often caused by diffuse hepatic cancer cell infiltration; however, in this case, it still occurred despite chemotherapy being effective. The shrinkage of liver metastases and subsequent scarring around them causes liver capsule regression, resulting in pseudocirrhotic changes. As a result of treatment for pseudocirrhosis, the once-atrophied liver regenerated and returned to its normal size after a year. Ascites and edema as portal pressure complications also disappeared. During this time, the liver metastases maintained a near-complete response. Cirrhosis accompanied by ascites is usually called \"decompensated cirrhosis\" and is considered difficult to improve; however, in pseudocirrhosis, the liver can regenerate and the patient can recover. Physicians must be fully aware of this disease.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"241-245"},"PeriodicalIF":0.5,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of autoimmune hemolytic anemia with cold agglutinin disease post-operation for recurrent ovarian cancer. 复发性卵巢癌术后自身免疫性溶血性贫血合并冷凝素病1例。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-03-17 eCollection Date: 2025-07-01 DOI: 10.1007/s13691-025-00758-x

Aisa Sugimoto, Hiroaki Yamada, Kazuto Tasaki, Takahiro Katsuda, Shin Nishio, Naotake Tsuda

{"title":"A case of autoimmune hemolytic anemia with cold agglutinin disease post-operation for recurrent ovarian cancer.","authors":"Aisa Sugimoto, Hiroaki Yamada, Kazuto Tasaki, Takahiro Katsuda, Shin Nishio, Naotake Tsuda","doi":"10.1007/s13691-025-00758-x","DOIUrl":"10.1007/s13691-025-00758-x","url":null,"abstract":"Autoimmune hemolytic anemia is a rare complication following surgery for recurrent ovarian cancer, with no previously reported cases of postoperative cold agglutinin disease. This report presents a 47-year-old woman who developed cold agglutinin disease after surgery for recurrent ovarian cancer. On postoperative day 7, she experienced severe anemia, renal dysfunction, and elevated bilirubin levels. Hemolysis was initially suspected owing to blood sampling and bleeding; however, autoimmune hemolytic anemia was diagnosed on postoperative day 8 with a positive Coombs test. Despite treatment with steroids, blood transfusions, and hemodialysis, the patient's condition remained unchanged. Cold agglutinin disease was confirmed on postoperative day 10 with a cold agglutinin titer of 512. Heated blood transfusions, along with rituximab and sutimlimab, led to clinical improvement. The patient was discharged on postoperative day 54 and continued on maintenance therapy. Stress from invasive surgery may activate the complement system, triggering cold agglutinin disease. Early diagnosis and treatment are crucial for preventing severe complications.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"235-240"},"PeriodicalIF":0.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Coexisting germline variants of MLH1 and MSH6 in a patient with Lynch syndrome who had uterine and ovarian cancer. Lynch综合征合并子宫癌和卵巢癌患者的MLH1和MSH6共存种系变异

IF 0.5

International Cancer Conference Journal Pub Date : 2025-03-03 eCollection Date: 2025-04-01 DOI: 10.1007/s13691-025-00753-2

Sho Umegaki, Masanobu Takahashi, Junko Hasegawa-Minato, Maako Kawamura, Sakura Taniguchi, Keigo Komine, Hideki Tokunaga, Kota Ouchi, Hiroo Imai, Ken Saijo, Hidekazu Shirota, Fumiyoshi Fujishima, Muneaki Shimada, Yoko Aoki, Chikashi Ishioka

{"title":"Coexisting germline variants of MLH1 and MSH6 in a patient with Lynch syndrome who had uterine and ovarian cancer.","authors":"Sho Umegaki, Masanobu Takahashi, Junko Hasegawa-Minato, Maako Kawamura, Sakura Taniguchi, Keigo Komine, Hideki Tokunaga, Kota Ouchi, Hiroo Imai, Ken Saijo, Hidekazu Shirota, Fumiyoshi Fujishima, Muneaki Shimada, Yoko Aoki, Chikashi Ishioka","doi":"10.1007/s13691-025-00753-2","DOIUrl":"10.1007/s13691-025-00753-2","url":null,"abstract":"Lynch syndrome is an autosomal dominant disorder caused by a heterozygous pathogenic germline variant in mismatch repair (MMR) genes including MLH1, MSH2, MSH6, PMS2, and EPCAM. This disease often causes a familial cluster of patients with malignant tumors. In this report, we describe a 37-year-old woman who presented with endometrioid carcinoma in the ovary and uterine corpus associated with Lynch syndrome. She carried two germline pathogenic variants, a recurrently reported MLH1 c.2250C > G (p.Tyr750*) and a previously unreported MSH6 c.2385del (p.Ile795Metfs*15). The tumor cells showed microsatellite instability. Immunohistochemistry for the endometrial tumor showed decreased MLH1 expression, loss of PMS2 expression, retained MSH2 expression, and loss of MSH6 expression, which suggests that both variants impair each protein stability and thus cause MMR deficiency. Whether these variants were inherited from her parents or occurred de novo was unknown. The tumor cells had somatic variants BRCA1 c.1016del and BRCA2 c.36dupT that might be due to secondary mutation by MMR deficiency. The use of an immune checkpoint inhibitor pembrolizumab resulted in durable partial response of metastatic lung tumors. This case reminds clinicians of the rare possibility of multiple germline variants in MMR genes in individuals with Lynch syndrome.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"171-176"},"PeriodicalIF":0.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of triple-negative breast cancer with thalassemia manifested by anemia progression during neoadjuvant chemotherapy. 三阴性乳腺癌伴地中海贫血在新辅助化疗期间表现为贫血进展。

IF 0.5

International Cancer Conference Journal Pub Date : 2025-03-03 eCollection Date: 2025-04-01 DOI: 10.1007/s13691-025-00755-0

Yoshinobu Fuse, Atsushi Fushimi, Eijirou Nagasaki, Takashi Kazama, Eriko Taguchi, Makiko Kamio, Hisashi Shioya, Yasuo Toriumi, Hiroshi Takeyama, Hiroko Nogi

{"title":"A case of triple-negative breast cancer with thalassemia manifested by anemia progression during neoadjuvant chemotherapy.","authors":"Yoshinobu Fuse, Atsushi Fushimi, Eijirou Nagasaki, Takashi Kazama, Eriko Taguchi, Makiko Kamio, Hisashi Shioya, Yasuo Toriumi, Hiroshi Takeyama, Hiroko Nogi","doi":"10.1007/s13691-025-00755-0","DOIUrl":"10.1007/s13691-025-00755-0","url":null,"abstract":"Thalassemia is an inherited hemoglobinopathy characterized by anemia. In Japan, beta-thalassemia occurs in only 1 in 1000 individuals, and reports of thalassemia in patients with breast cancer are extremely rare. We report a case of triple-negative breast cancer in which thalassemia manifested as progressive anemia during neoadjuvant chemotherapy. A Filipino woman in her 40 s with a family history of breast cancer presented with a left breast mass. Physical examination revealed a 2-cm palpable mass in the outer lower quadrant of the left breast. Ultrasonography confirmed a 21-mm irregular hypoechoic mass in the corresponding area with immunohistochemistry indicating a triple-negative phenotype (ER-, PgR-, HER2-negative, Ki-67 index 60%). Pembrolizumab, paclitaxel, and carboplatin were administered every 3 weeks, during which the hemoglobin (Hb) level gradually decreased. Thalassemia was diagnosed based on low pretreatment mean corpuscular volume (67.6 fL), presence of target cells in peripheral blood, and elevated fetal hemoglobin (HbF) levels. Despite the anemia progression, the patient was able to complete the planned chemotherapy regimen with blood transfusion support. This included 4 cycles of pembrolizumab, doxorubicin, and cyclophosphamide. Subsequently, a partial mastectomy plus sentinel lymph node biopsy was performed, and the patient achieved a pathological complete response. This case demonstrates that neoadjuvant chemotherapy for breast cancer can be successfully completed with appropriate blood transfusion support in patients with thalassemia-induced anemia.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"185-188"},"PeriodicalIF":0.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0